- The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's LLY rheumatoid arthritis drug for an initial portfolio of preferred medications to treat COVID-19, reports Reuters.
- The selection of drugs is part of the E.U. Strategy on COVID-19 therapeutics, launched in May.
- Top picks include Eli Lilly - Incyte Corporation's INCY Olumiant for hospitalized COVID-19 patients on oxygen, as well as new antibody drugs for early-stage disease from Regeneron Pharmaceuticals Inc REGN, Eli Lilly, Celltrion, and GlaxoSmithKline plc GSK - Vir Biotechnology Inc VIR.
- The Commission reiterated it would draw up a portfolio of at least ten potential COVID-19 therapeutics.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
